

[Home](#) > [About Us](#) > [Cancer.Net Editorial Board](#) > [Specialty Editors](#) > Andrew Ko, MD

Printed January 28, 2015 from <http://www.cancer.net/about-us/cancernet-editorial-board/specialty-editors/andrew-ko-md>

Andrew Ko, MD [1]



Cancer.Net Specialty Editor: Gastrointestinal Cancers

UCSF Comprehensive Cancer Center, San Francisco, CA

Andrew H. Ko, M.D., is an Associate Professor of Medicine at the University of California San Francisco (UCSF) Comprehensive Cancer Center. Dr. Ko specializes in the treatment of malignancies of the gastrointestinal (GI) tract, including esophageal, stomach, colorectal, pancreatic, and hepatobiliary cancers.

Dr. Ko graduated magna cum laude from Brown University and received his medical degree from Johns Hopkins School of Medicine. After an internship and residency at Beth Israel Hospital/Harvard Medical School in Boston, he completed a fellowship in medical oncology at Stanford University before joining the UCSF faculty in 2001.

Dr. Ko's clinical and research interests lie in new therapeutic approaches for GI malignancies with a particular focus in pancreatic cancer. He has been the principal investigator on a number of institutional and national clinical trials through collaborations with industry as well as funding from the National Cancer Institute. He has served in various capacities for ASCO, including serving as an editorial board member for the *Journal of Clinical Oncology*. He also sits on the National Comprehensive Cancer Network pancreatic cancer guidelines committee and co-chairs the scientific Protocol Review Committee at the UCSF Comprehensive Cancer Center.

Disclosure: In the past two years, Dr. Ko has received research funding from Celgene, Infinity Pharmaceuticals, ImClone Systems, PharmaEngine, Seattle Genetics, Pfizer, and ACT Biotech.

Last Updated: May 24, 2012

Links:

[1] <http://www.cancer.net/about-us/cancernet-editorial-board/specialty-editors/andrew-ko-md>